Trade: Will CRISPR Therapeutics (CRSP) beat quarterly earnings?

Market context

CRISPR Therapeutics will report first-quarter 2026 earnings on 5 May, with the Street consensus forecasting a loss of $1.26 per share on a GAAP basis. The market currently prices zero probability of the company beating that estimate—that is, reporting EPS greater than $1.26 in the negative direction. This extreme pricing reflects either deep conviction in consensus accuracy or minimal liquidity on Polymarket's order book for this contract; traders entering positions should examine both the bid-ask spread and recent order flow to understand whether the 0% reflects genuine market sentiment or thin depth.

CRISPR has historically missed earnings expectations during its clinical-stage phases, though the company has progressed toward commercialisation of its lead therapy, exagamglogene autotemcel (Casgevy), which received regulatory approval in late 2023. Comparable biotech firms trading on clinical-to-commercial transitions typically see earnings volatility driven by manufacturing ramp, patient uptake, and R&D spending patterns. A loss of $1.26 per share suggests the consensus expects material burn; beating that threshold would require either better-than-expected revenue recognition or lower-than-modelled operating expenses.

Key catalysts ahead of the earnings date include any commercial updates on Casgevy adoption, manufacturing capacity announcements, or partnership developments that might alter cash burn trajectories. Traders should monitor quarterly cash position disclosures and management guidance on 2026 spending, as these often precede formal earnings and can shift consensus estimates materially before the 5 May settlement window closes.

Resolution source

This market settles from the official outcome published at https://seekingalpha.com/. A proposer submits the final result to the UMA optimistic oracle on Polygon; the two-hour dispute window closes and payouts clear in USDC.

How to trade this market step by step

The mechanics for trading "Will CRISPR Therapeutics (CRSP) beat quarterly earnings?" are the same as any other PolyGram event contract. Each YES share resolves to $1 if the event happens, or $0 if it doesn't. The current price between 0¢ and 100¢ is the market's probability estimate, set live by the order book.

1. Sign in on polygram.ink with your email — no full KYC under $1,500 lifetime trading volume.
2. Deposit USDC on Polygon (lowest fees, ~$0.01 per transaction) or Ethereum. Funds credit after 12 confirmations.
3. Pick a side. Buy YES if you believe the event will happen; buy NO if you think it won't. The current YES price reflects the market's collective probability.
4. Size your position. If you stake 100 USDC at 0% YES, you'll receive shares that pay $200 if YES resolves true — a 100% gross return. If NO resolves, your shares are worth $0.
5. Set risk controls (optional). Stop-loss, take-profit, and limit-order types all supported. Use the trade ticket's slippage box to cap your maximum entry price.
6. Wait for resolution. When the event resolves on-chain via the UMA optimistic oracle, the winning side settles to 100¢ automatically and USDC hits your balance within seconds. Withdrawable to any wallet you control.

How active is this market?

$612 in lifetime turnover and $0 of resting liquidity puts this market in the below the median by volume for earnings contracts on PolyGram. Order-book depth is thin — large orders may need to be split across the book or executed as limit orders.

The market has been open for under a month — fresh enough that information asymmetry remains a real factor.

Higher-volume markets tend to have tighter spreads and faster price discovery — meaning the displayed YES/NO percentages are more likely to reflect the true crowd-implied probability rather than a single trader's directional view.

Key terms

YES / NO share

A binary outcome token that pays $1.00 if the underlying claim resolves true (YES) or false (NO), and $0 otherwise. The market price between 0¢ and 100¢ is the implied probability.

CLOB

Central limit order book. The matching engine that pairs YES buyers with NO buyers (effectively the same trade). Polymarket's CLOB on Polygon executes trades on-chain via the conditional-tokens framework.

Liquidity

USDC capital sitting in resting limit orders inside the order book. Deeper liquidity means smaller slippage on large trades and a tighter bid-ask spread.

UMA optimistic oracle

The on-chain dispute system that settles each Polymarket market. A proposer submits the outcome, a two-hour challenge window opens, and unchallenged proposals finalise the resolution.

Slippage

The difference between the displayed mid-price and your fill price. Affects market orders most; limit orders avoid slippage but may take time to fill.

Conditional token

ERC-1155 outcome share issued by Gnosis Conditional Tokens on Polygon. The token type that resolves to $1.00 or $0.00 at settlement.

See the full prediction-market glossary →

Frequently asked questions

Risk and regulatory note

Prediction-market positions can lose 100% of staked capital. Outcomes are uncertain by definition — historical accuracy of crowd-implied probabilities is high in aggregate but not for any single market. PolyGram does not provide investment advice. Trade only with capital you can afford to lose.

Regulatory status varies by jurisdiction. Germany, the United States, and most EU countries treat Polymarket-style event contracts under one of three frameworks: financial derivative, gambling product, or unregulated novel asset. Consult local counsel before trading.

Related prediction markets

Explore more prediction market odds and trading opportunities on PolyGram:

• All earnings prediction markets
• How prediction markets work
• Browse all prediction markets on PolyGram
• Top prediction market traders
• Back to PolyGram home